FUNDING INFORMATION
RTI
Novartis funded the CANTOS trial and the statistical analyses conducted for this manuscript. This post‐hoc analysis was investigator initiated. The funders approved the manuscript but were not otherwise involved in the conduct of this study. Dr. Orkaby is funded by VA CSR&D CDA‐2 award IK2‐CX001800 and reports consulting fees from Anthos Therapeutics. Ms. MacFadyen reports grants from Novartis during the conduct of the study. Dr. Ridker served as the Principal Investigator of the CANTOS trial which was funded by Novartis. Dr. Ridker has received institutional research grant support from Novartis, Kowa, Amarin, Pfizer, Esperion, NovoNordisk, and the NHLBI; has served as a consultant to Novartis, Flame, Agepha, AstraZeneca, Janssen, Civi Biopharm, Glaxo Smith Kline, SOCAR, Novo Nordisk, Omeicos, Health Outlook, Montai Health, New Amsterdam, Boehringer‐Ingelheim, RTI; Zomagen, Cytokinetics, Horizon Therapeutics, and Cardio Therapeutics; has minority shareholder equity positions in Uppton, Bitteroot Bio, and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA).